NEW YORK (GenomeWeb News) – The day after Sequenom's board of directors fired the firm's CEO and its senior VP of R&D, its shares tumbled 39 percent, and analysts who cover the firm noted a lack of clarity surrounding the investigation that led to the firing of those employees and surrounding the firm's technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.